Chemist Christopher Dobson Dies

The University of Cambridge scholar’s research on folding proteins advanced scientists’ understanding of illnesses, such as Alzheimer’s disease, Parkinson’s disease, and type 2 diabetes.

Written byAshley Yeager
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: WIKIMEDIA, JUSSI PUIKKONEN/KNAW

Christopher Dobson, a chemist knighted by the Queen of the UK in 2018, died last week (September 8) of pancreatic cancer. He was 69.

Dobson, a professor at the University of Cambridge, studied the structures and properties of biological molecules and was an expert on protein folding and aggregation. His “pioneering research investigating the origins of Alzheimer’s and Parkinson’s will undoubtedly lead to the discovery and introduction of new and effective treatments in the future that will benefit millions of people,” Frank Salmon, president of St. John’s College at the University of Cambridge, tells the Cambridge Independent. Dobson became the head of the college in 2007, which he led for 12 years. “His commitment to the college was apparent by the remarkable fact that he knew every fellow, student and member of staff by name,” Salmon says.

Dobson was born in Germany in 1949, the youngest ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies